Viamet Announces NIH Grant for Compounds Directed at Valley Fever

Viamet Pharmaceuticals, Inc. today announced that based upon progress achieved to date, an NIH grant for the development of novel antifungal agents for the treatment of Valley fever has been extended for a second year. The additional funding is intended to support advanced preclinical studies.